Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Dec 19:11:1758835919895755.
doi: 10.1177/1758835919895755. eCollection 2019.

Eribulin mesylate use as third-line therapy in patients with metastatic breast cancer (VESPRY): a prospective, multicentre, observational study

Vincenzo Adamo  1 , Giuseppina Rosaria Rita Ricciardi  2 , Dario Giuffrida  3 , Giuseppa Scandurra  4 , Antonio Russo  5 , Livio Blasi  6 , Pietro Spadaro  7 , Carmelo Iacono  8 , Hector J Soto Parra  9 , Antonino Savarino  10 , Francesco Ferraú  11 , Filippo Zerilli  12 , Francesco Verderame  13 , Alfredo Butera  14 , Carlo Santangelo  15 , Veronica Franchina  2 , Michele Caruso  16
Affiliations

Eribulin mesylate use as third-line therapy in patients with metastatic breast cancer (VESPRY): a prospective, multicentre, observational study

Vincenzo Adamo et al. Ther Adv Med Oncol. .

Abstract

Background: In real-world practice, eribulin mesylate provides significant survival benefit, with a manageable safety profile in heavily pretreated patients with metastatic breast cancer (MBC).

Methods: In this prospective, open-label, multicentre, observational study we evaluated the effectiveness and tolerability of eribulin as third-line treatment in a homogeneous population. The primary endpoints were the safety profile and response in metastatic sites; secondary endpoints included the response in different subtypes, overall response rate (ORR), progression-free survival (PFS) and overall survival (OS).

Results: From 2013 to 2016, 118 women were treated in 21 Sicilian institutions; the median age was 58 years (range 29-79), with 69% of patients under 65. The median cycles of eribulin were 5.5 (range 1-26). The most common adverse event was neutropenia (9.3%, 3 cases of grade 3, 4 of grade 4); only 1 case of QT prolongation was reported. Eribulin was effective in controlling metastatic disease in all sites, and it achieved the highest ORR in brain (16%) and liver (14.9%). Median OS was 31.8 months (95% CI 27.9-34.4) and median PFS 5.5 months (95% CI 4.2-6.6). PFS was 5.2 months (95% CI 2.8-8.4) in patients with triple-negative subtype. Median PFS was longer in patients over 65 years (6.1 months, 95% CI 4.4-8.3). In patients who had visceral metastases PFS was 5.5 months (95% CI 95% 3.5-6.6) and OS 33.9 months (95% CI 29.8-40.8).

Conclusions: Eribulin as third-line treatment shows an acceptable safety profile and a substantial antitumour activity in the treatment of MBC, even in elderly patients and in those with visceral disease.

Keywords: eribulin; metastatic breast cancer; multicentre; prospective; real world; third line.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest statement: The author(s) declare that there are no conflicts of interest.

Figures

Figure 1.
Figure 1.
Kaplan–Meier curve of PFS in (a) overall population and according to (b) age, (c) subtype and (d) visceral disease.
Figure 2.
Figure 2.
Kaplan–Meier curves of overall survival of overall population.
See this image and copyright information in PMC

References

    1. National Cancer Institute. SEER*Stat Databases: November 2012 Submission, https://seer.cancer.gov/data-software/documentation/seerstat/nov2012/ (2013).
    1. Moreno-Aspitia A, Perez EA. Treatment options for breast cancer resistant to anthracycline and taxane. Mayo Clin Proc 2009; 84: 533–545. - PMC - PubMed
    1. Goldhirsch A, Winer EP, Coates AS, et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer 2013. Ann Oncol 2013; 24: 2206–2223. - PMC - PubMed
    1. Towle MJ, Salvato KA, Wels BF, et al. Eribulin induces irreversible mitotic blockade: implications of cell-based pharmacodynamics for in vivo efficacy under intermittent dosing conditions. Cancer Res 2011; 71: 496–505. - PubMed
    1. Cortes J, O’Shaughnessy J, Loesch D, et al. Eribulin monotherapy versus treatment of physician’s choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet 2011; 377: 914–923. - PubMed

LinkOut - more resources